medigraphic.com

2004, Number 2

<< Back

Arch Cardiol Mex 2004; 74 (2)

Hypertension guidelines in Mexico

Rosas M, Pastelín G, Martínez RJ, Herrera-Acosta J, Attie F

Language: Spanish
References: 89
Page: 134-157
PDF size: 195.60 Kb.


Text Extraction

No abstract


REFERENCES

  1. Presentación

  2. Valles V, Arroyo P, Fernandez V, Herrera J, Kuri-Morales P, Olaiz G, Tapia-Conyer, R: The Mexican ministry of Health conducted a national survey of chronic disease in 1992-3. Hypertension 1999; 33: 1094.

  3. Velazquez-Monroy O, Rosas PM, Lara EA, Pastelin HG, Castillo C, Attie F, Tapia CR: Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Arch Cardiol Mex 2003; 73(1): 62-77.

  4. Guías de Hipertensión

  5. Mascie-Taylor CG, Karim E: The burden of chronic disease. Science 2003; 302: 1921-1922.

  6. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hans-Werner H, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto Jaakko, Vanuzzo D, Vescio F: Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.

  7. Valles V, Arroyo P, Fernandez V, Herrera J, Kuri-Morales P, Olaiz G, Tapia-Conyer R: The Mexican Ministry of Health conducted a national survey of chronic disease in 1992-3. Hypertension 1999; 33: 1094.

  8. Velazquez-Monroy O, Rosas PM, Lara EA, Pastelin HG, Castillo C, Attie F, Tapia Conyer R: Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Arch Cardiol Mex 2003; 73(1): 62-77.

  9. Shumei Meng, Cason GW, Gannon AW, Racusen LC, Manning RDJr: Oxidative Stress in Dahl Salt-Sensitive Hypertension. Hypertension 2003; 41: 1346-1352.

  10. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.

  11. U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih.gov/about/nhbpep/index.htm. Accessed March 5, 2003.

  12. Sheps SG, Roccella EJ: Reflections on the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Curr Hypertens Rep 1999; 1: 342-5.

  13. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Mechanisms of Disease: Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension. N Engl J Med 2002; 346: 913-23.

  14. Roccella EJ, Kaplan NM: Interpretation and evaluation of clinical guidelines. In: Izzo JL Jr, Black HR, eds. Hypertension Primer. Dallas, TX: American Heart Association, 2003; 126: 126-7.

  15. Vasan RS, Larson MG, Leip EP, et al: Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-6.

  16. Vasan RS, Beiser A, Seshadri S, et al: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10.

  17. Lewington S, Clarke R, Qizilbash N, et al: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.

  18. Rosas M: Arterial hypertension in Mexico and its association with other risk factors. Arch Cardiol Mex 2003; 73(Suppl 1): S137-40.

  19. Velasquez MO, Rosas PM, Lara EA, Pastelin HG, Attie F, Tapia CR: Grupo Encuesta Nacional de Salud 2000. Arterial hypertension in Mexico: results of the National Health Survey 2000. Arch Cardiol Mex 2002; 72(1): 71-84.

  20. Feinstein AR: Multivariable Analysis: An introduction. New Haven Connecticut: Yale University Press, 1996: 297-369.

  21. Himmelmman A, Kjldsen SE: Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC. Blood Press 2003; 12(4): 196-7.

  22. Lohr KN: Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 2004; 16(1): 9-18.

  23. Feinstein AR: “Clinical Judgment” revisited: the distraction of quantitative models. Ann Intern Med 1994; 120: 799-805.

  24. World Hypertension League. Measuring your blood pressure. Available at: http://www.mco.edu/org/whl/bloodpre.html. Accessed April 1, 2003.

  25. Pickering T: Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel. Am J Hypertens 1996; 9: 1-11.

  26. Verdecchia P: Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35: 844-51.

  27. American Heart Association. Home monitoring of high blood pressure. Available at: http://www.americanheart.org/presenter.jhtml? identifier=576. Accessed April 1, 2003.

  28. Chobanian AV, Hill M: National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: A critical review of current scientific evidence. Hypertension 2000; 35: 858-63.

  29. Karter Y, Curgunlu A, Altinisik S, Erturk N, Vehid S, Mihmanli I, Ayan F, Kutlu A, Arat A, Ozturk E, Erdine S: Target organ damage and changes in arterial compliance in white coat hypertension. Is white coat innocent? Blood Press 2003; 12(5-6): 307-13.

  30. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. NEJM 2000; 342: 836-843.

  31. Backes JM: Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004; 38(1): 110-8.

  32. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y: Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; [Epub ahead of print].

  33. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, De Jong PE, Gans RO, De Zeeuw D: C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria. Hypertension 2004; [Epub ahead of print].

  34. Miyazaki M: Angiotensin II in organ organopathy. Nippon Rinsho 2004; 62(1): 21-7.

  35. Parrinello G, Colomba D, Bologna P, Licata A, Pinto A, Paterna S, Scaglione R, Licata G: Early carotid atherosclerosis and cardiac diastolyc abnormalities in hypertensive subjects. J Hum Hypertens 2004; 18(3): 201-5.

  36. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L: Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin Nephrol 2004; 24(2): 147-57.

  37. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.

  38. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB: Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol 2003; 42(7): 1199-205.

  39. Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlof B: Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens 2001; 14(8 Pt 1): 775-82.

  40. Eren M, Gorgulu S, Uslu N, Celik S, Dagdeviren B, Tezel T: Relation between aortic stiffness and left ventricular diastolyc function in patients with hypertension, diabetes, or both. Heart 2004; 90(1): 37-43.

  41. Kern R, Szabo K, Hennerici M, Meairs S: Characterization of Carotid Artery Plaques Using Real-time Compound B-mode Ultrasound. Stroke 2004; [Epub ahead of print].

  42. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004; 109(9): 1089-94. Epub 2004 Mar 01.

  43. Fathi R, Haluska B, Isbel N, Short L, Marwick TH: The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43(4): 616-23.

  44. Stehouwer CD: Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19(4): 778-81.

  45. Carreiro-Lewandowski E: Update on selected markers used in risk assessment for vascular disease. Clin Lab Sci 2004; 17(1): 43-9.

  46. Ruilope LM, Segura J, Campo C, Rodicio JL: Renal participation in cardiovascular risk in essential hypertension. Expert Rev Cardiovasc Ther 2003; 1(2): 309-315.

  47. Cockroft D, Gault MK: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

  48. Alderman M, Aiyer KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20(3): 369-79.

  49. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183-90.

  50. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Johnson RJ: A single pathway for the development of essential hypertension. Cardiol Rev 2003; 11(4): 180-96.

  51. Johnson RJ, Rodriguez-Iturbe B, Herrera-Acosta J: Nephron number and primary hypertension. N Engl J Med 2003; 348(17): 1717-9.

  52. Klein R, Klein BE, Tomany SC, Wong TY: The relation of retinal microvascular characteristics to age-related eye disease: the Beaver Dam eye study. Am J Ophthalmol 2004; 137(3): 435-44.

  53. Wong TY: Is retinal photography useful in the measurement of stroke risk? Lancet Neurol 2004; 3(3): 179-83.

  54. Dahlof B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC: Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004; [Epub ahead of print].

  55. Sidorenko BA, Preobrazhenskii DV, Soplevenko AV, Ivanova NA, Stetsenko TM: Candesartan - a Novel AT(1)-Angiotensin Receptor Blocker: Peculiarities of Pharmacology and Experience of Use in Arterial Hypertension Kardiologiia. 2004; 44(1): 55-65.

  56. Demaerschalk BM: Diagnosis and management of stroke (brain attack). Semin Neurol 2003; 23(3): 241-52.

  57. Cusi D, Barlassina C, Taglietti MV: Genetics of human arterial hypertension. J Nephrol 2003; 16(4): 609-15.

  58. Touyz RM, Schiffrin EL: Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003; 81(6): 533-41.

  59. Weinberger MH: Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens 2002; 4: 274-6.

  60. Manning RD Jr, Hu L, Tan DY, Meng S. Role of abnormal nitric oxide systems in salt-sensitive hypertension. Am J Hypertens 2001; 14(6 Pt 2): 68S-73S.

  61. Lucas CP, Estigarribia JA, Darga LL, Reaven GM: Insulin and blood pressure in obesity. Hypertension 1985; 7: 702-706.

  62. Modan M, Halkin H, Almog S, Lusky A, Eshkil A, Shefi M, Shitrit A, Fuchs A: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.

  63. Ferrannini E, Buzzigoli G, Bonadona R: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.

  64. Shen D-C, Shieh S-M, Fuh M, Wu D-A, Chen Y-DI, Reaven GM: Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580-583.

  65. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-423.

  66. Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-174.

  67. Mbanya JC, Wilkinson R, Thomas T, Alberti K, Taylor R: Hypertension and hyperinsulinemia: a relation in diabetes but not in essential hypertension. Lancet 1988; I: 733-734.

  68. Collins VR, Dowse GK, Finch CF, Zimmet PZ: An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin Epidemiol 1990; 43: 1369-1378.

  69. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Havard VV, Bogardus C: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991; 324: 733-739.

  70. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H: For the European Group for the Study of Insulin Resistance (EGIR) Insulin resistance, hyperinsulinemia, and blood pressure. Role of age and obesity. Hypertension 1992; 30: 1144-1149.

  71. Marigliano A, Tedde R, Sechi LA, Para A, Pisanu G, Pacifico A: Insulinemia and blood pressure: relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. Am J Hypertens 1990; 3: 521-526.

  72. Shamiss A, Carroll J, Rosenthall T: Insulin resistance in secondary hypertension. Am J Hypertens 1992; 5: 26-28.

  73. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y, Heynen G: Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589-596.

  74. Facchini F, Chen Y-DI, Clinkingbeard C, Jeppesen J, Reaven GM: Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens 1992; 5: 694-699.

  75. Allemann Y, Horber FF, Colombo M, Ferrari P, Shaw S, Jaeger P, Weidman P: Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet 1993; 341: 327-331.

  76. Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Otsuka K, Saruta T: Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensive: possible role of disturbed calcium metabolism. J Hypertens 1993; 11: 421-426.

  77. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM: Insulin resistance in offspring of hypertensive parents. BMJ 1993; 307: 92-96.

  78. Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991; 9: 217-223.

  79. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797-801.

  80. Taittonen L, Uhari M, Nuutinen M, Turtinen J, Pokka T, Akerblom HK: Insulin and blood pressure among healthy children. Am J Hypertens 1996; 9: 193-199.

  81. Raitakari OT, Porkka KVK, Rönnemaa T, Knip M, Uhari M, Akerblom HK, Viikari JSA: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. Diabetologia 1995; 38: 1042-1050.

  82. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall’Aglio E, Delsignore R, Reaven GM: Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism 1994; 48: 989-994.

  83. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Asyndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-911.

  84. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM: Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000; 23: 171-175.

  85. Reaven GM: Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease. J Clin Endocrinol Metab 2003; 88: 2399-2403.

  86. Mancia G, Mark AL: Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, Md: American Physiological Society; 1983: 755-793.

  87. Mancia G, Grassi G, Ferrari AU: Reflex control of the circulation in experimental and human hypertension. In: Zanchetti A, Mancia G, eds. Handbook of Hypertension, Vol 17: Pathophysiology of Hypertension. Amsterdam, Netherlands: Elsevier Science; 1997: 568-601.

  88. Collidge TA, Lammie GA, Fleming S, Mullins JJ: The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. Prog Biophys Mol Biol 2004; 84: 301-19.

  89. Tuncel M, Ram VC: Hypertensive emergencies: etiology and management. Am J Cardiovasc Drugs 2003; 3: 21-31.




2020     |     www.medigraphic.com